Cumberland Pharmaceuticals is a specialty pharmaceutical
company focused on the acquisition, development and commercialization of
branded prescription products. The company’s product portfolio currently
features five marketed treatments – including Acetadote®, Caldolor®,
Kristalose®, Vaprisol® and Omeclamox-Pak® – addressing its primary target
markets of hospital acute care and gastroenterology. Cumberland owns the
worldwide rights to all of its brands, allowing the company to focus on the
U.S. market while actively pursuing strategic partnerships and other
opportunities to make its products available to patients in underserved
international markets.
In the second quarter of 2015, Cumberland’s strongest
performing product was Kristalose, which accounted for $4.1 million in net
revenue. As the only branded prescription laxative product that features the
established safety and efficacy of lactulose in a pre-measured powder dose,
Kristalose offers patients a virtually tasteless, grit-free and essentially
calorie-free alternative to lactulose syrups. In a 2009 study by Clinical and
Experimental Gastroenterology, the company’s product was preferred by 83
percent of patients, highlighting the immense market potential of Cumberland’s product
portfolio moving forward.
In addition to its commercialized products, Cumberland is
currently engaged in late-stage clinical development of two promising drug
candidates. Hepatoren® is being developed to treat patients suffering from
hepatorenal syndrome, while Boxaban® is being developed for the treatment of
aspirin-exacerbated respiratory disease. Enrollment for phase II studies of
both candidates is underway and expected to be completed by the end of 2015. To
ensure reliable expansion of its product portfolio in the future, Cumberland
also operates Cumberland Emerging Technologies (CET), which, in collaboration
with some of the country’s top universities, is providing the company with a
long-term pipeline of new product candidates.
As of June 30, 2015, Cumberland reported approximately $93
million in total assets, including $53 million in cash and investments, with
only $14.2 million in total liabilities. In the coming months, the company will
look to leverage the flexibility offered by this balance sheet to promote
long-term, sustainable growth.
“We remain in a strong financial position with a solid
balance sheet and profitable operations,” A.J. Kazimi, chief executive officer
of Cumberland, stated in a news release. “We are working to maximize the
potential of our five commercial products and actively pursuing the addition of
new brands to our portfolio.”
With an established product portfolio, a promising
development pipeline and a steady supply of new candidates provided by CET,
Cumberland is in a strong strategic position to expand upon its considerable
industry presence in the years to come. For prospective shareholders, the
company’s favorable balance sheet and persistent commitment to expanding upon
its market share could foreshadow an opportunity for Cumberland to achieve
sustainable returns for the foreseeable future.
For more information, visit www.cumberlandpharma.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
